Endogenex
Company

Last deal

$88M

Amount

Series C

Stage

25.06.2024

Date

3

all rounds

$113M

Total amount

date founded

Financing round

General

About Company
Endogenex develops an endoscopic procedure to improve glycemic control in patients with Type 2 Diabetes.

Industry

Sector :

Subsector :

Also Known As

DyaMX

founded date

01.01.2017

Operating Status

Closed (01.01.2020)

Number of employees

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

Endogenex is a clinical stage company that aims to enhance the quality of life of patients suffering from Type 2 Diabetes. Their innovative therapy employs pulsed electric fields to regenerate the duodenal mucosa, which results in better glycemic control. Endogenex's procedure is endoscopic and non-invasive, which means it is less risky than traditional surgical procedures. Their therapy is still in the clinical trial phase, but it shows promising results in improving outcomes for patients with Type 2 Diabetes.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Fractyl Health

Fractyl Health

Fractyl Health uses Revita DMR to rejuvenate the lining of the duodenum.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Lexington, MA, USA

total rounds

9

total raised

$310.19M
SageMedic

SageMedic

SageMedic develops a genome-free SAGE Direct Platform that increases clinical success rates for drugs in development.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Redwood City, CA, USA

total rounds

4
Biohope

Biohope

Biohope develops diagnostic and therapeutic solutions for organ transplantation.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Madrid, Spain

total rounds

3

total raised

$394.41K
Invizius

Invizius

Invizius is a biotech company developing treatments to help hemodialysis patients live longer and feel better.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Edinburgh, UK

total rounds

5

total raised

$13.56M

Financials

Funding Rounds
6
3

Number of Funding Rounds

$113M

Money Raised

Their latest funding was raised on 25.06.2024. Their latest investor Hatteras Venture Partners. Their latest round Series C

Date 
Funding Round 
Investors 
Money Raised 
Lead 
25.06.2024
7
$88M
20.04.2021
$12M
05.12.2018
$12.76M
Co-Investors
Investors
8
1

Number of lead investors

8

Number of investors

Investor 
Lead 
Round 
Partners 
Hatteras Venture Partners

Hatteras Venture Partners

Hatteras Venture Partners invests in transformative companies in healthcare and related fields.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Keywords

Venture Capital, Health Care, Financial Services

Location

Durham, NC, USA

count Of Investments

96

count Of Exists

16
Longitude Capital

Longitude Capital

Longitude Capital is a venture capital firm that invests in biotechnology and medical technology companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Menlo Park, CA, USA

count Of Investments

111

count Of Exists

16
Juliet Tammenoms Bakker

Juliet Tammenoms Bakker

Ms. Bakker is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Ms. Bakker was a Managing Director of Pequot Ventures where she founded the life sciences investment practice. Prior to Pequot, she was Director, Strategic Planning and Director, Operations of Waste Management International. Previously, she was a sell-side equity analyst with Banque Paribas. Ms. Bakker began her career as an investment banker in the corporate finance department at PaineWebber. She currently serves on the boards of Alphaeon, Axonics Modulation Technologies, Encore Dermatology, Nalu, RxSight and Venus Concept. She has previously served on the boards of Ablation Frontiers (acquired by Medtronic), AqueSys (acquired by Allergan), CryoVascular Systems (acquired by Boston Scientific), Embolic Protection (acquired by Boston Scientific), Enteric Medical (acquired by Boston Scientific), eyeonics (acquired by Bausch+Lomb), Genyx Medical (acquired by C.R.Bard), Insulet (PODD), Precision Dermatology (acquired by Valeant Pharmaceuticals), and Sadra Medical (acquired by Boston Scientific). Ms. Bakker holds an M.P.A. from the John F. Kennedy School of Government at Harvard University and a B.Sc. from the College of Agriculture and Life Sciences at Cornell University (“CALS”), where she is a member of the CALS Advisory Council. Ms. Bakker is also a board member of the Boys and Girls Club of Greenwich.

current job

Longitude Capital
Longitude Capital
Intuitive Ventures

Intuitive Ventures

Intuitive Ventures supports early-stage start-ups to reach their major milestones.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services

Location

Sunnyvale, CA, USA

count Of Investments

12

People

Founders
3

Paul Hindrichs

Paul Hindrichs is a veteran business leader and innovator with more than 20 years of medical device experience. He has served in various management capacities during his career, including positions with several other start-up and early stage medical device companies. Prior to founding Conventus, he worked for St. Jude Medical (SJM), Vascular Science, Inc., Optical Sensors, Inc., and Schneider USA (Pfizer). Most recently, he was responsible for the Structural Heart Business and Cardiac Technologies Group at SJM. Mr. Hindrichs earned a Bachelor of Science in Mechanical Engineering from the University of Minnesota and is a named inventor on 20 issued and 22 pending patent applications.

current job

Endogenex
Endogenex

organization founded

2

Paul Hindrichs

Michael Brenzel

Michael Brenzel is the Co-Founder of DyaMX.

current job

Endogenex
Endogenex

organization founded

1

Michael Brenzel

John Deedrick
John Deedrick

John Deedrick

John A. Deedrick is the Co-founder and Managing Director of Fourth Element Capital, a healthcare technology venture capital firm. He is Co-founder and Executive Chairman of ActivOrtho, Inc., DyaMX, Inc., CHIP II, Inc., as well as FourMation Medical Works, a new healthcare technology business creation and growth company. John is also President of CHIP Solutions, a business consulting firm that provides significant value-added services to individuals, private companies and public companies. From 2003-2012, John was a Co-founder and General Partner with Accuitive Medical Ventures (AMV). AMV has over $230 million in capital under management in its two medical device venture capital funds. AMV has a proprietary relationship with The Innovation Factory (TIF), a medical device incubator located in Duluth, GA. John was instrumental in fundraising, investment and management committee activities, building the portfolio and harvesting returns for AMV’s Limited Partners. John served as a Director for AMV’s investments in MyoScience, SoftScope, Nevro and Torax. He was significantly involved in deal flow, due diligence and risk identification/management for all AMV portfolio companies. Key exits from the portfolio include LipoSonix (Medicis), SoftScope Medical (Fujinon), Sadra Medical (Boston Scientific), Axogen (AXGN), Inogen (INGN), Wavetec (Alcon), Nevro (NVRO), AqueSys (Allergan), Torax Medical (JJ Ethicon) and most recently Neuronetics (STIM). Prior to joining AMV, John was a Venture Manager for Mayo Clinic Ventures (MCV). During his time at MCV, John managed investments in several emerging medical companies including Exact Sciences (EXAS), Circe Biomedical (Arbios), Ascension Orthopedics (Integra), Neotonus, CardiacAssist (LivaNova), Image-Guided Neurologics (Medtronic), TomoTherapy (AcuRay), Cerebral Vascular Applications (licensed), and Volcano Therapeutics (Philips). In addition, he was instrumental in the start-up of four Mayo-founded companies: Santarus (Salix), Copharos, TeraMedica (Fujifilm), and Torax Medical (J&J Ethicon).

current job

Endogenex
Endogenex

count Of Investments

1

John Deedrick

Employee Profiles
3
John Deedrick

John Deedrick

Co-Founder and Executive Chairman

Michael Brenzel

Co-Founder

Paul Hindrichs

Co-Founder

Activity

Recent News
2
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month